Aplagon

Aplagon is a Finnish private biotech founded in 2018, advancing APAC, a novel vascular injury-targeting molecule with combined antiplatelet, anticoagulant, and anti-inflammatory properties. The company is currently in Phase 2a clinical trials for Peripheral Arterial Occlusive Disease/Chronic Limb Threatening Ischemia, having secured EUR 7 million in financing in early 2025 to advance this program. Backed by leading Finnish investors and based on pioneering research from the Wihuri Research Institute, Aplagon aims to address the significant unmet need in thrombotic cardiovascular diseases where current therapies are only partially effective.

APAC, a synthetic heparin proteoglycan mimetic with triple action (antiplatelet, anticoagulant, anti-inflammatory) designed to target sites of vascular injury.

Aplagon competes in the large and competitive anti-thrombotic drug market, dominated by generics (e.g., aspirin, clopidogrel, warfarin) and newer DOACs. Its differentiation is the localized, triple-action approach targeting thromboinflammation, a niche not fully addressed by current standard-of-care combination therapies. Competitors include other companies developing novel antiplatelets, anticoagulants, and anti-inflammatory agents for vascular diseases.